PepGen Inc. PEPG

Updated: 10 Aug 2026

NASDAQ | Biotech | Biotechnology

No signal published yet

We already track PepGen and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow PepGen free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology
We're already tracking PepGen Inc. — here are the latest events we've registered

Recent News

  • On August 6, 2026, PepGen reported its second-quarter 2026 financial results and announced that an independent monitoring board recommended dose escalation for PGN-EDODM1 in its Phase 2 FREEDOM2 trial. The company ended June 2026 with $117.2 million in cash and marketable securities, which it expects to fund operations into the fourth quarter of 2027.

What Firelda Watch includes for PepGen Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of PepGen Inc. will be delivered in the same format.

Want to follow PepGen Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow PepGen free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

PepGen Inc. PEPG
PepGen — follow and we'll monitor it
Follow PepGen free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.